Collaboration, License, and Other Agreements (Tables)

6 Months Ended

Jun. 30, 2020

Revenue from Contract with Customer [Abstract]

In arrangements where we do not deem our collaborator to be our customer, payments to and from our collaborator are presented in our statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below.


Nature/Type of Payment						Statement of Operations Presentation
Regeneron's share of profits or losses in connection with commercialization of products						Collaboration revenue
Reimbursement for manufacturing of commercial supplies						Collaboration revenue
Royalties and/or sales-based milestones earned						Collaboration revenue
Reimbursement of Regeneron's research and development expenses						Reduction to Research and development expenses
Regeneron's obligation for its share of collaborator's research and development expenses						Research and development expense
Up-front and development milestone payments to collaborator						Research and development expense
Reimbursement of Regeneron's commercialization-related expenses						Reduction to Selling, general, and administrative expense
Regeneron's obligation for its share of collaborator's commercialization-related expenses						Selling, general, and administrative expense
Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal						Cost of goods sold
Up-front and development milestones earned (when we have a combined unit of account which includes a license and providing research and development services)						Other operating income

Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below:


	Statement of Operations Classification	Three Months Ended June 30,									Six Months Ended June 30,
				2020			2019			2020			2019
Antibody:
Regeneron's share of profits in connection with commercialization of antibodies	Sanofi collaboration revenue	$	171.9		$	38.8		$	342.8		$	11.0
Reimbursement for manufacturing of commercial supplies	Sanofi collaboration revenue	$	100.6		$	43.9		$	180.7		$	58.4
Reimbursement of research and development expenses	Reduction of Research and development expense	$	51.3		$	81.8		$	128.9		$	156.3
Regeneron's obligation for its share of Sanofi research and development expenses	Research and development expense	$	(24.9)		$	(12.2)		$	(41.6)		$	(19.6)
Reimbursement of commercialization-related expenses	Reduction of Selling, general, and administrative expense	$	86.0		$	121.1		$	177.2		$	237.7

Immuno-oncology:
Regeneron's share of losses in connection with commercialization of Libtayo outside the United States	Sanofi collaboration revenue	$	(6.4)		$	(6.9)		$	(12.6)		$	(11.6)
Reimbursement for manufacturing of commercial supplies	Sanofi collaboration revenue	$	3.0		—			$	5.1		—
Reimbursement of research and development expenses	Reduction of Research and development expense	$	47.0		$	36.5		$	86.9		$	82.9
Reimbursement of commercialization-related expenses	Reduction of Selling, general, and administrative expense	$	14.3		$	1.8		$	24.7		$	4.0
Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits	Cost of goods sold	$	(28.2)		$	(19.0)		$	(55.0)		$	(31.4)
Amounts recognized in connection with up-front payments received	Other operating income	$	20.5		$	29.0		$	37.0		$	55.3

Amounts recognized in our Statements of Operations in connection with our Bayer EYLEA collaboration are as follows:


	Statement of Operations Classification	Three Months Ended June 30,									Six Months Ended June 30,
				2020			2019			2020			2019
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	Bayer collaboration revenue	$	230.9		$	269.0		$	484.7		$	518.3
Reimbursement for manufacturing of commercial supplies	Bayer collaboration revenue	$	13.3		$	8.2		$	40.9		$	22.9
Reimbursement of development expenses	Reduction of Research and development expense	$	10.8		$	8.0		$	22.8		$	10.6
Regeneron's obligation for its share of Bayer research and development expenses	Research and development expense	$	(5.3)		$	(2.0)		$	(13.4)		$	(6.6)
Reimbursement of other expenses	Cost of collaboration and contract manufacturing	$	1.6		$	4.1		$	3.3		$	12.9

Amounts recognized in our Statements of Operations in connection with the Teva Collaboration Agreement are as follows:


	Statement of Operations Classification	Three Months Ended June 30,									Six Months Ended June 30,
				2020			2019			2020			2019
Reimbursement of research and development expenses	Reduction of Research and development expense	$	31.0		$	36.5		$	56.2		$	68.7
Amounts recognized in connection with up-front and development milestone payments received	Other operating income	$	20.7		$	24.5		$	37.3		$	46.0

Summary of contract balances

The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:


	June 30,		December 31,
	2020		2019
Accounts receivable	$	383.1	$	272.7
Deferred revenue	$	405.5	$	328.8

The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:


	June 30,		December 31,
	2020		2019
Accounts receivable, net	$	(2.2)	$	(16.7)
Deferred revenue	$	12.5	$	9.4
Other liabilities	$	486.7	$	558.6

The following table summarizes contract balances in connection with our Bayer EYLEA collaboration:


	June 30,		December 31,
	2020		2019
Accounts receivable - other	$	245.8	$	311.6
Deferred revenue	$	125.3	$	123.0

The following table summarizes contract balances in connection with the Teva Collaboration Agreement:


	June 30,		December 31,
	2020		2019
Accounts receivable - other	$	28.5	$	21.2
Other liabilities	$	77.9	$	114.4